Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Ouabain (HB1140)
Description:Selective Na+ / K+ ATPase inhibitor. Shows antiviral activity.
Purity:>98%
-
Palitantin (HB4012)
Description:Metabolite of Penicillium with antiprotozoal and antifungal activity
Purity:>95%
- Description:
PKC activator. Widely used for THP-1 cell differentiation and with ionomycin for stimulating cytokine production
Purity:>99%
-
-
Puromycin dihydrochloride (HB4041)
Description:Protein synthesis inhibitor. Cell culture selection antibiotic.
Purity:>98%
